VIDEO: KEYNOTE-966 study bodes well for future bile tract cancer studies
In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.
Kaseb, a professor in the department of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, highlighted the study, which tested a combination therapy of pembrolizumab and gemcitabine/cisplatin in patients with biliary tract cancer, and showed statistically significant progression-free survival.
“Even though the survival benefit is modest, this will work for us as a validation of the benefit of immunotherapy in bile duct cancers, and we’ll see more buildup of that in future studies,” Kaseb said.
Collapse
Read more about